



## Financial Tear Sheet

### Corporate Profile

ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD's first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. Additional clinical trials of Iclusig in other cancers are ongoing. ARIAD is also studying AP26113, another molecularly targeted medicine, in certain forms of lung cancer.


### Primary IR Contact

Manmeet Soni  
Chief Financial Officer  
ARIAD Pharmaceuticals,  
Inc.  
**Phone:**617-503-7298  
**E-mail:**  
manmeet.soni@ariad.com

### Stock Performance

|                           |                    |
|---------------------------|--------------------|
| <b>Exchange</b>           | NASDAQ (US Dollar) |
| <b>Price</b>              | \$23.99            |
| <b>Change (%)</b>         | 0.00 (0.00%)       |
| <b>Volume</b>             | 0                  |
| <b>52 Week Low</b>        | \$4.67             |
| <b>Market Cap</b>         | \$4,658,878,679    |
| <b>Rolling EPS</b>        | -0.18              |
| <b>PE Ratio</b>           | 0                  |
| <b>Shares Outstanding</b> | 194,200,862        |

Data as of 02/15/17 4:15 p.m. ET



## Recent Headlines & Events

04/28/17 - 6:53 p.m.

Takeda Announces FDA Accelerated Approval of ALUNBRIG™ (brigatinib)

02/16/17 - 8:56 a.m.

Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.

02/06/17 - 7:35 a.m.

ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency

There are currently no events scheduled.

## Analyst Estimates / Ratings

### Mean Recommendation:

Sell                      Strong Buy

### EPS Trend

Current    30 Days Ago    90 Days Ago

QTR

QTR

QTR

QTR

FY

FY

## SEC Filings

| Filing Date | Form     |
|-------------|----------|
| 04/07/17    | SC 13G/A |
| 02/27/17    | CT ORDER |
| 02/27/17    | 15-12B   |
| 02/21/17    | SC 13D/A |

## Corporate Governance

|                         |   |
|-------------------------|---|
| Harvey J. Berger, M.D.  | Chairman and Chief Executive Officer                          |
| David Berstein, Esq.    | Senior Vice President and Chief Intellectual Property Officer |
| Daniel M. Bollag, Ph.D. | Senior Vice President of Regulatory Affairs and Quality       |
| Joseph Bratica          | Vice President, Finance and Controller                        |

|                                |   |
|--------------------------------|---|
| Maria E. Cantor                | Senior Vice President,<br>Corporate Affairs   |
| Timothy P. Clackson, Ph.D.     | President of Research<br>and Development and<br>Chief Scientific Officer                                  |
| David C. Dalgarno, Ph.D.       | Vice President, Research<br>Technologies  |
| Jonathan E. Dickinson          | Vice President, European<br>Operations and General<br>Manager, ARIAD<br>Pharmaceuticals<br>(Europe), Sarl |
| Pierre F. Dodion, M.D., M.B.A  | Senior Vice President,<br>Corporate Development<br>and Operations   |
| Martin J. Duvall               | Senior Vice President,<br>Commercial Operations   |
| Edward M. Fitzgerald           | Executive Vice President,<br>Chief Financial Officer<br>and Treasurer                                     |
| Frank G. Haluska, M.D., Ph.D.  | Chief Medical Officer and<br>Senior Vice President,<br>Clinical R&D                                       |
| Shirish Hirani, Ph.D.          | Vice President, Program<br>and Alliance Management  |
| Stephen R. Jamieson            | Vice President,<br>Information Technology   |
| Raymond T. Keane, Esq.         | Senior Vice President,<br>General Counsel,<br>Secretary and Chief<br>Compliance Officer                   |
| Ronald K. Knickerbocker, Ph.D. | Vice President,<br>Biomedical Data Sciences<br>and Information  |

|                               |  |
|-------------------------------|--|
| Jing L. Marantz, M.D., Ph.D.  | Vice President, Medical Affairs                        |
| Victor M. Rivera, Ph.D.       | Vice President, Preclinical and Translational Research |
| William C. Shakespeare, Ph.D. | Vice President, Drug Discovery                         |

## Ownership Summary

|             | Holders | Value (\$MM) | % O/S | Shares     |
|-------------|---------|--------------|-------|------------|
| Institution | 41      | 160.79       | 0.0   | 12,185,490 |
| Mutual Fund | 44      | 147.37       | 0.0   | 9,658,885  |
| Insider *   | 8       | .00          | 0.0   | 1,264,810  |

\*Insider values reflect direct beneficial ownership.

### Top Holders

|  | Shares Held | % O/S | Share Change | Filing Date |
|--|-------------|-------|--------------|-------------|
| Berger (Harvey J)                        | 4,371,103   | 0.0   | 0            | 05/20/16    |
| Norges Bank Investment Management (NBIM) | 2,339,750   | 0.0   | 295,757      | 12/31/16    |
| Odey Asset Management LLP                | 1,991,643   | 0.0   | 1,991,643    | 01/31/17    |
| LaMarche (Jay R)                         | 549,526     | 0.0   | -9,375       | 05/20/16    |
| Groupama Asset Management                | 342,234     | 0.0   | 25,499       | 12/31/16    |
| Fitzgerald (Edward M)                    | 320,995     | 0.0   | 0            | 05/20/16    |
| UOB Asset Management Ltd.                | 252,590     | 0.0   | 252,590      | 12/31/16    |
| Alean (Capital) Anstalt                  | 240,000     | 0.0   | 240,000      | 06/30/16    |
| Clackson (Timothy P)                     | 215,855     | 0.0   | 19,723       | 01/31/17    |
| Bellevue Research, Inc.                  | 175,000     | 0.0   | 0            | 11/30/15    |

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources